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BACKGROUND: Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predictive markers to identify the most
adequate treatment for each patient are needed. Our objective was to identify potential predictive markers of sunitinib activity in
MRCC.
METHODS: We collected sequential serum samples from 31 patients treated with sunitinib. Sera of six patients with extreme
phenotypes of either marked responses or clear progressions were analysed with a Human Cytokine Array which evaluates 174
cytokines before and after treatment. Variations in cytokine signal intensity were compared between both groups and the most
relevant cytokines were assessed by ELISA in all the patients.
RESULTS: Twenty-seven of the 174 cytokines varied significantly between both groups. Five of them (TNF-a, MMP-9, ICAM-1, BDNF
and SDF-1) were assessed by ELISA in 21 evaluable patients. TNF-a and MMP-9 baseline levels were significantly increased in non-
responders and significantly associated with reduced overall survival and time-to-progression, respectively. The area under the ROC
curves for TNF-a and MMP-9 as predictive markers of sunitinib activity were 0.83 and 0.77.
CONCLUSION: Baseline levels of TNF-a and MMP-9 warrant further study as predictive markers of sunitinib activity in MRCC. Selection
of patients with extreme phenotypes seems a valid method to identify potential predictive factors of response.
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Treatment of metastatic renal cell carcinoma (MRCC) has rapidly
evolved during the past years, with the development of several new
targeted agents. Sunitinib (Sutent; Pfizer Inc., New York, NY,
USA) and the combination of bevacizumab and interferon have
shown superiority over single-agent interferon in randomized
phase III trials as first-line treatment of MRCC (Motzer et al, 2007;
Escudier et al, 2007b; Rini et al, 2008a). Temsirolimus was also
superior to interferon in patients with poor prognosis MRCC
(Hudes et al, 2007). Finally, sorafenib and everolimus have also
shown efficacy in the second-line setting (Escudier et al, 2007a;
Motzer et al, 2008b). Even though clinical algorithms that
recommend the most appropriate agent according to each clinical
situation and previous treatments have been developed (Motzer
et al, 2008c), predictive markers of activity to determine the most
appropriate treatment for each patient are urgently needed to
maximise the clinical benefit and to spare unnecessary toxicities
and costs.
Selection of predictive markers of response is an intricate task,
given the large number of potential targets to analyse. High-
throughput techniques have the advantage of being able to
evaluate several molecular factors at one time, but their
interpretation and their translation into clinical practice is
somewhat cumbersome. The selection and study of individuals
with very characteristic and clinically relevant phenotypes has
been proposed as a methodology that may help to characterize the
factors underlying such phenotypes (Perez-Gracia et al, 2002).
This strategy consists of selecting and screening with high-
throughput techniques of those patients presenting the most
informative clinical features, rather than whole unselected series of
patients, to improve the probability of finding factors that might
be linked with such phenotypes. We employed this methodology
to identify potential predictive factors of response to sunitinib
in MRCC.
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sMATERIALS AND METHODS
From November 2004 to October 2006, we obtained sequential
serum samples from 31 consecutive patients with MRCC treated
with sunitinib at our institution, while participating in the phase
III sunitinib registration study (Motzer et al, 2007) and in an
expanded use trial. Patients received sunitinib (50mg per 24h)
during 4 weeks followed by a 2-week resting period between cycles.
Follow-up and toxicity management were performed following the
study protocol. Response was evaluated every two cycles using
RECIST criteria (Therasse et al, 2000). Blood samples were
obtained from patients at baseline and at the moment of first
evaluation of response at the end of the second cycle (day 28).
Serum was obtained after blood centrifugation at 1500r.p.m. for
10min at 41C. Samples were aliquoted and stored at  801C. Both
trials, as well as the protocol to obtain blood samples were
approved by our institution’s Ethics Committee, and all patients
signed the respective informed consents.
The methodology of extreme phenotype selection was used for
this study (Perez-Gracia et al, 2002). Three patients with very
marked clinical responses to sunitinib and three with clear
progressions, despite adequate performance status, absence of
comorbidities and correct treatment administration, were selected
by the attending clinicians. Sera were analysed with a cytokine
array that is described below. The most relevant candidate
cytokines, in terms of statistical significance and biological
plausibility, were selected and they were assessed in the rest of
the patients using ELISA.
High-throughput serum cytokine assay
In a first set of experiments we sought to identify serum cytokines
that were modulated by sunitinib in MRCC patients. A Human
Cytokine Antibody Array (Series 2000, RayBiotech, Norcross, GA,
USA), which has been clinically validated (Ray et al, 2007), was
used to analyse 174 human cytokines related to angiogenesis,
immunity and tumour proliferation pathways (the complete list of
cytokines is available as Supplementary Material, Appendix 1).
Sera of three patients with an excellent response to sunitinib and of
three non-responders were analysed with the array. The baseline
cytokine array profile was compared with that found after
treatment for each patient. Samples were analysed according to
the manufacturer’s instructions. Briefly, wells of the microarray
glass slides were blocked in blocking buffer for 30min and
subsequently incubated with 1:5 diluted samples (90ml per well)
overnight at 41C. Slides were washed in washing buffer and
incubated with a biotin-conjugated cocktail of antibodies for 2h.
After further washing, horseradish peroxidase (HRP)-conjugated
streptavidin was incubated for 2h. To visualise bound antibodies,
samples were incubated with Alexa flour 555-conjugated strepta-
vidin in darkness for 2h. Detection of signals was assessed with a
GMS 418 array scanner (Genetic Microsystems, Woburn, MA,
USA). Spots signal intensities were imported into a GMS array
scanner programme for analysis.
Array data normalisation and analysis
Positive control signals on each array were used as normalization
factor following the manufacturer’s instructions. For each
cytokine, baseline intensity levels were compared with those found
after treatment and fold-change differences were calculated. Global
loess-based normalization was performed using Bioconductor
(Gentleman et al, 2004) and ratios were scaled based on the
median absolute deviation. Filtering of flat profiles was applied
using a variation coefficient value of 0.5. Statistical comparison of
the two experimental conditions was performed using the
Wilcoxon test, and the obtained P-value was corrected for multiple
hypotheses testing using the False Discovery Rate (FDR) method
for array analysis. The FDR of a test is defined as the expected
proportion of false positives among the declared significant results
(Benjamini and Hochberg, 1995, 2000; Keselman et al, 2002). The
selection of cytokines for ELISA validation was based on an FDR
threshold of 10% (Storey and Tibshirani, 2003).
ELISA
Serum samples obtained at baseline and at the moment of response
evaluation were assayed by ELISA (RayBiotech), following the
manufacturer’s protocol, for TNF-a, MMP-9, ICAM-1, BDNF,
VEGF, and SDF-1. Briefly, 96-well plates were incubated at 41C
overnight with standards at different concentrations, and serum
samples. After several washes, wells were incubated with
biotinylated antibodies for 1h, followed by HRP-conjugated
streptavidin for 45min. Enzymatic reactions were developed and
the absorbance was measured at 450nm (A450) in a SunRise
(Tecan, Salzburg, Austria) ELISA plate reader. Protein levels were
calculated according to standard curves.
Statistical methods
Array data was analysed as described above. Statistical differences
between groups were examined using the Student’s t-test for
unpaired and paired data for parametric variables, and the
Mann–Whitney U-test for unpaired non-parametric variables.
The Wilcoxon test was used to study paired non-parametric
variables. Normality was tested using Shapiro–Wilks Test. Data
were analysed with the SPSS statistical software (version 15.0 for
Windows SPSS). P-values o0.05 were considered significant and
95% confidence intervals were calculated. Time-to-event variables
were assayed with the Kaplan–Meier test. Survival curves were
compared with the Log-rank test. Risk of lack of response was
measured by exact logistic regression (pack logXact V.8).
Sensitivity, specificity, predictive values, and receiver operator
characteristic (ROC) curves, as well as their confidence intervals
were computed with Epitable from Epiinfo v6.1. Discriminant
function analysis and Cox regression were performed with SPSS.
RESULTS
Variations in serum levels of 27 cytokines from the array
showed significant differences between responders and
non-responders
Twenty-seven of the 174 cytokines assayed by the array were able
to cluster the patients in two different groups and to discriminate
those with marked clinical responses (n¼3) from those with clear
disease progression (n¼3), according to the FDR method for
array analysis, using a threshold of 10% (Figure 1). Levels of
cytokines such as matrix metalloproteinase-9 (MMP-9), tumour
necrosis factor-a (TNF-a) and brain-derived neurotrophic factor
(BDNF) increased exclusively in non-responding patients, as
compared with responders. Conversely, other soluble proteins
such as intercellular adhesion molecule-1 (ICAM-1), macrophage
inflammatory protein 3b, stromal cell-derived factor-1 (SDF-1)
and interleukin-17 decreased significantly only in non-responders
and either did not change or were increased in responders.
Baseline levels of MMP-9 and TNF-a predict clinical
benefit of sunitinib
From the 27 cytokines modulated by sunitinib identified by the
cytokine array, five (TNF-a, MMP-9, ICAM-1, BDNF, and SDF-1)
were selected for further quantitative analysis by ELISA in the
whole patient series, based on statistical significance and on
biological plausibility of the involvement of such cytokines in renal
cell carcinoma. TNF-a was selected because recent reports have
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sdemonstrated its involvement in renal carcinoma development,
and targeted therapies using anti-TNF-a have been recently shown
to be efficacious against this tumour (Harrison et al, 2007). MMP-
9, whose levels are significantly high in MRCC patients, induces
VEGF availability (Hawinkels et al, 2008). BDNF upregulates
MMP-9 levels and promotes its activation (Sun et al, 2006) and,
therefore, was also considered for validation by ELISA. SDF-1 was
suggested by previous studies as a target for renal carcinoma
therapy (Reckamp et al, 2008), and increased levels of this cytokine
have been shown in sunitinib-treated mice (Ebos et al, 2007).
ICAM-1 levels were also checked for validation, because plasma
levels of this cytokine have been associated with a response to the
anti-VEGF targeting agent bevacizumab in combination with
docetaxel in metastatic breast cancer (Ramaswamy et al, 2006).
Vascular endothelial growth factor (VEGF) was quantified as well,
because its receptors are primary targets of sunitinib.
Clinical characteristics of the patients are summarised in
Table 1. All the patients presented metastatic renal clear-cell
carcinoma. The analysis was performed in 21 evaluable patients.
Ten patients were not evaluable, due to lack of follow-up
information (three patients) or adequate sequential serum samples
(seven patients). Twelve patients showed clinical benefit (response
or disease stabilisation) and nine patients presented tumour
progression.
Baseline levels of TNF-a and MMP-9 were significantly higher
(Po0.05) in patients who progressed (Figure 2, Table 2) than in
patients with no progression, whereas no differences were seen for
the rest of the cytokines (Table 2). To measure the accuracy of the
MMP-9 and TNF-a ELISA tests to predict a lack of response to
sunitinib, sensitivity (S), specificity (Sp), positive (PPV) and
negative (NPV) predictive values, and area under the ROC curves
were calculated. For MMP-9, using the upper tercile (4062ngml
 1)
as a cutoff value, data were as follows: S: 55.6% (95% CI: 22.7–
84.7); Sp: 75% (95% CI: 42.8–93.3); PPV: 62.5 (95% CI: 25.9–89.8);
NPV: 69.2 (95% CI: 38.9–89.6). For TNF-a, using the median (50
pgml
 1) as a cutoff value, the following results were obtained: S:
88% (95% CI: 50.7–99.4); Sp: 75% (95% CI: 42.8–93.3); PPV:
72.7% (95% CI: 39.3–92.7); NPV: 90% (95% CI: 54.1–99.5). Areas
under the ROC curves for TNF-a and MMP-9 were 0.828 and 0.768,
respectively.
Exact logistic regression showed that increasing MMP-9 levels
were associated with a significant increase in the risk of no
response (OR¼2.84; 95% CI: 1.11–10.44, P¼0.024), whereas
TNF-a levels did not show such association. A stepwise
discriminant function analysis further revealed that MMP-9 levels
are better predictors of clinical benefit than TNF-a levels. The
discriminant model showed that MMP-9 levels over 4062ngml
 1
significantly (P¼0.027) predicted sunitinib’s lack of clinical
benefit (Wilk’s l¼0.767; w
2¼4.913).
Baseline levels of MMP-9 and TNF-a are associated with
survival
Median time-to-progression (TTP) for the whole group of patients
was 7.03 months (95% CI: 5.51–8.55) (Figure 3A) and median
overall survival (OS) was 11.27 months (95% CI: 4.88–17.65)
(Figure 3B). Median OS of patients with TNF-a baseline levels
above the median (50 pgml
 1) was 7 months (s.d.: 1.491; 95% CI:
4.078–9.92), as compared with 20 months (s.d.: 6.803; 95% CI:
6.65–33.34, P¼0.045) for the other patients (Figure 3C). A
significant association between TNF-a levels higher than
50pgml
 1 and reduced OS was found (P¼0.045). TTP correlation
with baseline TNF-a levels, approached, but did not reach
statistical significance (P¼0.07). For MMP-9, using the median
as a cutoff value, no differences were observed. However, levels
above the upper tercile (4062ngml
 1) showed a significant
Table 1 Patient characteristics
Characteristics N (%)
Sex
Male 23 (74)
Female 8 (26)
Age
Median 58
Range 40-83
Performance status
0 20 (64)
1 10 (34)
2 1 (2)
Tumour histology
Clear-cell carcinoma 31 (100)
Response to sunitinib
Partial response 13 (42)
Stable disease 4 (13)
Progression 14 (45)
Previous treatment lines
None 13 (42)
1 11 (35)
2 3 (10)
X3 4 (13)
Previous treatments
Low-dose cytokines 15 (48)
Bevacizumab 6 (19)
Other 5 (16)
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Figure 1 Cluster analysis of antibody-based cytokine microarray in
patients treated with sunitinib. Fold-change between baseline levels and
levels at the time of evaluation of response were analysed in three patients
with response (left columns) and three patients with progression (right
columns). The analysis shows that fold-change levels of 27 cytokines cluster
responders from non-responders into two different groups.
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sassociation with reduced TTP (P¼0.042). Patients with MMP-9
levels above that value had a median TTP of 3 months (s.d.: 0.598;
95% CI: 1.83–4.17) as compared with 8 months (s.d.: 1.88; 95% CI:
4.33–11.67) for patients below that limit (Figure 3D). No
association was observed between MMP-9 baseline levels and OS
(P¼0.515).
Cox-regression analysis showed a significant interaction
between both MMP-9 and TNF-a levels in predicting the risk of
reduced TTP: HR for the interaction was 10.323 (95% CI: 1.028–
103.64, Po0.047), whereas HR for TNF-a alone was 2.63 (95% CI:
0.986–7.058, P¼0.053) and for MMP-9 alone, 3.05 (95% CI: 1.09–
8.51, P¼0.033).
MMP-9, SDF-1, and BDNF serum levels are modulated by
sunitinib
Baseline levels of the cytokines quantified by ELISA were
compared with those measured at the moment of response
evaluation. MMP-9, SDF-1, and BDNF levels significantly changed
upon treatment (Figure 4), whereas TNF-a, VEGF, and ICAM-1 did
not vary. Sunitinib significantly decreased MMP-9 levels in both
patient groups (P¼0.011 for patients with clinical benefit, and
P¼0.005 for patients with progression). BDNF levels also
decreased in both groups (P¼0.016 and P¼0.011, respectively).
On the contrary, SDF-1 levels increased significantly (Po0.004) in
patients presenting clinical benefit, whereas in patients who
progressed, the increment approached statistical significance
(P¼0.08, Figure 4). Therefore, MMP-9, SDF-1, and BDNF seem
novel cytokines modulated by sunitinib.
DISCUSSION
Several new agents are available for treatment of MRCC and many
others are under clinical development, leading to a situation in
which the choice of the optimal therapy for each patient is
sometimes unclear. Predictive markers of clinical benefit are
needed to select the most appropriate treatment for each patient.
In an attempt to improve the yield of our study, we selected
patients with phenotypes of either marked responses or clear
progressions and we screened their serum samples with a protein
array assessing 174 cytokines. This allowed us to select the
cytokines that significantly clustered both groups of patients.
Quantitative analysis by ELISA of those cytokines in the entire
group of patients confirmed that TNF-a and MMP-9 baseline levels
were significantly higher in non-responders. In addition, the area
under the ROC curves of TNF-a and MMP-9 indicated good
accuracy for both markers as predictive factors of sunitinib clinical
benefit. These results suggest that baseline serum levels of TNF-a
and MMP-9 warrant further evaluation in future studies as
predictive markers of sunitinib activity in patients with MRCC.
Our study also supports that our methodological approach seems
useful to select candidate predictive factors of clinical benefit of a
determined treatment, and that it can reveal alternative pathways
that might be relevant to understand the drug’s mechanism of
action.
Metalloproteinase-9 (MMP-9) belongs to the family of matrix
metalloproteases and has a key role in promoting angiogenesis and
metastasis (Bergers et al, 2000). In the bone marrow, VEGF and
SDF-1-mediated activation of MMP-9 releases soluble Kit-ligand,
permitting the mobilisation of endothelial and hematopoietic stem
cells (Heissig et al, 2002). Elevated serum levels of MMP-9 are
associated with tumour invasion and metastatic spread in a variety
of malignancies. Serum levels and tissue expression of MMP-9 are
higher in renal cell carcinoma as compared with healthy controls
(Lein et al, 2000). Tissue MMP-9 levels in renal cell carcinoma
samples are strongly associated with high nuclear grade (Kawata
et al, 2007) and shortened survival (Kallakury et al, 2001).
Pathological regulation of TNF-a has been related to primary
and metastatic cancer promotion, directly or via a complex
network of cytokines, chemokines, and matrix metalloproteases
(Kulbe et al, 2007). TNF-a can be secreted by immune-related cells
and tumour cells, and it has been suggested to act in an autocrine/
paracrine way to promote cancer development (Harrison et al,
2007). Both TNF-a and its receptors are coexpressed by renal
carcinoma cells and, upon binding, the expression of angiogenesis-
MMP- 9 (baseline levels) TNF- (baseline levels)
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Figure 2 Determination by ELISA of serum baseline levels of TNF-a (A) and MMP-9 (B) in MRCC patients treated with sunitinib. Inbox bars show
median levels for each cytokine of each group of patients. (TNF-a: 20pgml
 1 for responders, and 103.3 pgml
 1 for non-responders; MMP-9: 3303.9ngml
 1
for responders, and 4262.4ngml
 1 for non-responders). A significant increase in non-responders compared with responders is found.
Table 2 Statistical comparison of mean baseline cytokine levels quantified by ELISA between patients presenting clinical benefit or progression
Cytokines Clinical benefit (mean±s.d) Progression (mean±s.d.) P-value
TNF-a (pgml
 1) 76.94±194.73 164.07±134.80 0.009
MMP-9 (ngml
 1) 2972.31±1337.31 4227.3±933.73 0.027
ICAM-1 (ngml
 1) 445.7±103.77 482.2±157.99 0.900
VEGF (ngml
 1) 19.57±17.85 14.27±4.38 0.382
SDF-1 (pgml
 1) 49.17±32.87 61.86±29.33 0.371
BDNF (ngml
 1) 16.67±8.64 13.61±6.11 0.378
Bold values are statistically significant.
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srelated genes such as VEGF (Yoshida et al, 1997) and IL-6 has been
reported (Ng et al, 1994). The potential involvement of TNF-a in
renal cancer has been recently demonstrated. High affinity
antibodies that target TNF-a, preventing its binding to TNF-aR1
and R2 receptors are clinically available for treatment of
rheumatoid arthritis and Crohn’s disease. Such antibodies have
also been tested as treatment for MRCC at standard and high
doses in 37 patients, producing partial responses in three patients
(8%) and stabilizations in 11 patients (30%) (Harrison et al, 2007).
They also reported that baseline TNF-a levels were predictive of
clinical benefit. These results along with ours highlight the
potential role of TNF-a as a biomarker in MRCC and support
the possibility of combining sunitinib with TNF-a blocking
therapies.
We have also identified by high-throughput analysis that SDF-1
and BDNF are modulated by sunitinib. SDF-1 is secreted by
carcinoma-associated fibroblasts and stimulates cancer cell growth
directly through the CXCR4 receptor expressed on tumour cells,
and also recruits endothelial progenitor cells into tumours,
thereby fostering neoangiogenesis (Orimo and Weinberg,
2006). The SDF-1/CXCR4 pathway has been suggested as a target
for renal cancer therapy (Reckamp et al, 2008), and dose-
dependent increases in SDF-1 levels have been reported previously
in normal nontumour-bearing mice treated with sunitinib in a
previous study (Ebos et al, 2007), which further supports
our results. BDNF is a novel angiogenic factor that upregulates
MMP-2 and MMP-9 and promotes their activation (Sun et al,
2006). Interestingly, anti-BDNF antibodies in multiple myeloma
models produce inhibition of tumour growth and angiogenesis
(Hu et al, 2007). Expression of the BDNF receptor (TrkB) in
Wilm’s tumours is associated with poor prognosis, probably
because it provides autocrine growth-stimulating signals (Eggert
et al, 2001). BDNF/TrkB should be considered in future studies to
assess its potential role as a biomarker and therapeutical target in
renal carcinoma.
Other studies have evaluated different potential biomarkers of
sunitinib activity. HIFa and 2a levels in cell lines and in human
tumours have been shown to correlate with clinical response to
sunitinib in patients with MRCC (Patel et al, 2008). Low baseline
levels of sVEGFR-3 and VEGF-C have been associated with a longer
TTP and an improved response rate (Rini et al, 2008b). Other
investigators have reported that patients with gastrointestinal
stromal tumours that showed clinical benefit with sunitinib had a
reduced number of circulating endothelial cells and monocytes, as
compared with patients who did not respond (Norden-Zfoni et al,
2007). Greater variations in VEGF, sVEGFR-2, and s-VEGFR-3 were
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Figure 3 Kaplan–Meier plots of time-to-progression (A) and overall survival (B) in the complete group. Baseline levels of TNF-a above the median are
significantly associated (P¼0.045) with reduced overall survival (C). MMP-9 levels over the upper tercile are significantly associated (P¼0.042) with
decreased time-to-progression (D).
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sobserved in patients presenting objective tumour responses than in
patients with stable disease or progression (Deprimo et al, 2007).
Finally, some clinical factors have been evaluated as predictors of
clinical activity. Motzer et al, (2008a) have developed a clinical
nomogram that predicts the probability of a 12-month TTP in
patients treated with sunitinib. Rini et al (2008c), have shown that
high levels of diastolic blood pressure during treatment with
axitinib, a potent and selective inhibitor of VEGFR1, 2 and 3, shows
a marked correlation with survival in a series of patients with
different tumours. Choueiri et al (2007) have reported that five
clinical factors, – time-to-diagnosis, baseline calcium and platelet
and neutrophil counts and performance status are independent
prognostic factors for patients with MRCC treated with anti-VEGF
therapy and have developed a prognostic model that categorizes
such patients into three prognostic groups. These potential
predictive factors of activity, along with those determined in our
study should be assessed in prospective trials to provide a more
accurate prediction of sunitinib activity.
The main limitations of our study are the lack of standardisation
of current tools to determine serum TNF-a and MMP-9 levels as
well as the limited sample size. Yet, these limitations are partially
overcome by previous reports that also support a role for
TNF-a and MMP-9 in MRCC, as reviewed above. In any case,
confirmatory studies will be required to corroborate if baseline
serum levels of TNF-a and MMP-9 are clinically useful in
this setting. If so, the use of these markers might be relevant
for further development of sunitinib in other tumour types.
Additional research will be required to determine if the predictive
value of TNF-a and MMP-9 is specific of sunitinib or if
they can also be used to predict activity of other drugs used to
treat MRCC.
In conclusion, baseline serum levels of MMP-9 and TNF-a merit
further study as predictive markers of sunitinib activity in patients
with MRCC. Extreme phenotype selection in combination with
high-throughput analysis is a valid method to identify candidates
who might prove to be useful predictive factors of activity in
cancer treatments.
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